Orthofix Medical Management
Management criteria checks 0/4
Orthofix Medical's CEO is Massimo Calafiore, appointed in Jan 2024, has a tenure of 1.33 years. total yearly compensation is $10.65M, comprised of 7.5% salary and 92.5% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth €571.27K. The average tenure of the management team and the board of directors is 1 years and 1.7 years respectively.
Key information
Massimo Calafiore
Chief executive officer
US$10.6m
Total compensation
| CEO salary percentage | 7.45% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1yr |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$143m |
| Dec 31 2024 | US$11m | US$793k | -US$126m |
Compensation vs Market: Massimo's total compensation ($USD10.65M) is above average for companies of similar size in the German market ($USD920.27K).
Compensation vs Earnings: Insufficient data to compare Massimo's compensation with company performance.
CEO
Massimo Calafiore (52 yo)
1.3yrs
Tenure
US$10,645,026
Compensation
Mr. Massimo Calafiore is President, CEO & Director of Orthofix Medical Inc. from January 8, 2024 and was Interim President of Global Spine from January 10, 2024. Mr. Massimo Calafiore was the Chief Executi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$10.65m | 0.13% € 571.3k | |
| Chief Financial Officer | 1.3yrs | US$3.19m | 0.016% € 69.3k | |
| Chief Accounting Officer | 1.3yrs | US$917.93k | 0.020% € 84.3k | |
| Chief Legal Officer & Corporate Secretary | 1.1yrs | US$2.50m | 0.015% € 62.7k | |
| Chief People & Business Operations Officer | less than a year | US$4.13m | 0.029% € 125.0k | |
| President of the Global Spine Business | less than a year | US$2.99m | 0% € 0 | |
| President of Global Operations & Quality | less than a year | no data | 0.0065% € 27.9k | |
| Chief Investor Relations & Communications Officer | less than a year | no data | no data | |
| Chief Compliance & Risk Officer | no data | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| President of Global Biologics | 2.3yrs | no data | no data | |
| Chief Enabling Technologies Officer | no data | no data | no data |
1.0yrs
Average Tenure
52.5yo
Average Age
Experienced Management: OM2's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.3yrs | US$10.65m | 0.13% € 571.3k | |
| Independent Director | 2.3yrs | US$274.29k | 0.10% € 449.1k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 1.4yrs | US$379.45k | 0.073% € 314.4k | |
| Independent Director | 4.9yrs | US$296.20k | 0.015% € 65.8k | |
| Independent Director | 1.4yrs | US$375.19k | 0.0024% € 10.3k | |
| Independent Chair of the Board | 1.4yrs | US$472.32k | 0% € 0 | |
| Independent Director | 9.2yrs | US$291.92k | 0.034% € 146.7k | |
| Independent Director | 2.3yrs | US$270.01k | 0.015% € 62.6k | |
| Independent Director | 1.9yrs | US$274.29k | 0.016% € 69.8k |
1.7yrs
Average Tenure
61yo
Average Age
Experienced Board: OM2's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 09:37 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orthofix Medical Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Chodaczek | Boenning & Scattergood, Inc. |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |